Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Shary Shelton"'
Publikováno v:
Radiation Oncology, Vol 18, Iss 1, Pp 1-14 (2023)
Abstract Background The management of ultracentral thoracic tumors with ablative dose of radiotherapy remains challenging given proximity to critical central structures. We report patient outcomes, toxicity, and dosimetry for ultracentrally located t
Externí odkaz:
https://doaj.org/article/d22885b156a54e65a45d6309944e4567
Publikováno v:
PLoS ONE, Vol 7, Iss 8, p e42226 (2012)
Appropriate responses to damaged DNA are indispensible for preserving genome stability and preventing cancer. Tumor viruses often target DNA repair machinery to achieve transformation. The Human T-cell leukemia virus type I (HTLV-I) is the only known
Externí odkaz:
https://doaj.org/article/69d85587d0e8448686a16aafe1636887
Autor:
Matthew Mallory, Kevin Kauweloa, Hinrich Staecker, Paul Camarata, Roukoz Chamoun, Rishi Neeranjun, Rajeev Badkul, Mindi TenNapel, Shary Shelton, Fen Wang
Publikováno v:
Journal of Radiotherapy in Practice. 22
Introduction: This study was aimed to evaluate the outcomes of patients with large (>2 cm in great diameter) vestibular schwannomas (VSs) treated with hypofractionated stereotactic radiotherapy (HFSRT) compared to small ( Methods: Fifty-nine patients
Autor:
Dhruv Kumar, Vikalp Vishwakarma, Jacob New, Radhika Joshi, Fangchen Lin, Sumana Dasari, Wade Gutierrez, Hemant Chavan, Ossama Tawfik, Shary Shelton, Yelizaveta Shnayder, Kiran Kakarala, Terance Tsue, Douglas Girod, Bennett Van Houten, Partha Kasturi, Sufi M. Thomas
Publikováno v:
Cancer Research. 76:1030-1030
Head and neck squamous cell carcinoma (HNSCC) is an aggressive malignancy affecting 40,000 cases in the USA annually. Despite aggressive therapies HNSCC is associated with less than a 50% 5-year survival rate. Limited treatment options and high morbi